Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: A system includes a first communication device and a second communication device in communication with the first communication device via an Ethernet connection. The first communication device is configured to transmit, via the Ethernet connection toward the second communication device, an Ethernet signal including information of a designated wavelength from a dense wavelength division multiplexing (DWDM) scheme to be used by the second communication device. The second communication device is configured to transmit an optical signal at the designated wavelength to the first communication device in response to receiving the Ethernet signal.

Abstract: An apparatus includes a first reconfigurable optical add/drop multiplexer (ROADM) to receive a first optical signal and a second ROADM to receive a second optical signal. The apparatus also includes a reconfigurable optical switch that includes a first switch, switchable between a first state and a second state, to transmit the first optical signal at the first state and block the first optical signal at the second state. The reconfigurable optical switch also includes a second switch, switchable between the first state and the second state, to transmit the second optical signal at the first state and block the second optical signal at the second state. The reconfigurable optical switch also includes an output port to transmit an output signal that is a sum of possible optical signals transmitted through the first switch and the second switch.

Abstract: An apparatus includes a first input port, a first switch, and a second switch. The first switch and the second input port are in optical communication with the first input port. The apparatus also includes a second input port, a third switch, and a fourth switch. The third switch and the fourth switch are in optical communication with the second input port. Each switch is switchable between a first state to pass optical signals and a second state to block optical signals. The apparatus also includes a first combiner in optical communication with the first input port via the first switch and the second input port via the third switch. The apparatus also includes a second combiner in optical communication with the first input port via the second switch and the second input port via the fourth switch.

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: A gimbal (200) has an intermediate plate (202), a first plate (204) offset from the intermediate plate (202) in a first direction, a first bearing (208) having a first rotational axis connected between the intermediate plate (202) and the first plate (204), a second plate (206) offset from the intermediate plate (202) in a second direction opposite the first direction, and a second bearing (210) having a second rotational axis connected between the intermediate plate (202) and the second plate (206).

Abstract: A low latency metadata subsystem for file systems in low latency (LL) mode in a distributed file storage service (DFSS). An LL server (LLS) may receive metadata requests from an access node of the DFSS. For read operations, the LLS may check a local cache of metadata and, for cache hits, retrieve the metadata from the cache. For cache misses, the metadata may be fetched from the storage subsystem of the DFSS and cached. For write operations, the LLS may write entries into a journal for the file system and notify the access node after the journal entries are committed to the journal; the journal entries are asynchronously committed in the storage subsystem. The access node may communicate with the storage subsystem to perform data reads and writes for the LL file system.

Abstract: This disclosure relates to systems and methods for managing documents and other electronic works. Certain embodiments relate to enabling secure, governed, and/or audited collaboration and/or document management over cloud storage platforms (e.g., third-party cloud storage platforms). Further embodiments relate to providing key and rights management as well as collaboration services in conjunction with cloud storage services.

Abstract: Systems, methods and cartridges for carbonating or otherwise dissolving gas in a precursor liquid, such as water, to form a beverage. A gas source can be provided in a cartridge which is used to generate gas that is dissolved into the precursor liquid. A beverage medium, such as a powdered drink mix or liquid syrup, may be provided in the same, or a separate cartridge as the gas source and mixed with the precursor liquid to form a beverage. The use of one or more cartridges for the gas source and/or beverage medium may make for an easy to use and mess-free system for making sparkling beverages, e.g., in the consumer's home.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: In an automatically switched optical network operating according to a wavelength plan, the wavelengths are assigned to an optical path based on availability, performance and SRS wavelength coupling reduction. First, the wavelengths are grouped in static bins based on their reach versus cost performance, and each bin assumes a ?Q of a middle wavelength. Then, the bins are moved into subsets of dynamic bins, constructed using bin constraints that account for the particulars of the respective optical path. The path is characterized taking into account the wavelength currently accessing at the end nodes, and the wavelength tandeming through the end nodes. Wavelength selection starts with the bins that satisfy the maximum number of constraints, and the wavelengths are checked sequentially against wavelength constraints; relaxed constraints are also applied when it is not possible to exactly satisfy one or more constraints.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A? are C or N, where C may be substituted by halo or C1-C6 alkyl; R and R0 are selected from the group consisting of H, C1-C6 alkyl, —(CH2)n—W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, —NR?SO2—R?, etc., where R? and R? are C1-C6 alkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and Ro and the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; R1 is H, halo or cyano; R2 and R2? are H, C1-C6 alkyl, etc.; X is a bond, etc.; R3 is H, C1-C4 alkyl, etc.; Y is a bond, —(CH2)m—, etc. The invention also relates to compositions and uses in the treatment of various diseases.

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: Systems, methods and cartridges for carbonating or otherwise dissolving gas in a precursor liquid, such as water, to form a beverage. A gas source can be provided in a cartridge which is used to generate gas that is dissolved into the precursor liquid. A beverage medium, such as a powdered drink mix or liquid syrup, may be provided in the same, or a separate cartridge as the gas source and mixed with the precursor liquid to form a beverage. The use of one or more cartridges for the gas source and/or beverage medium may make for an easy to use and mess-free system for making sparkling beverages, e.g., in the consumer's home.

Abstract: Systems, methods and cartridges for carbonating or otherwise dissolving gas in a precursor liquid, such as water, to form a beverage. A gas source can be provided in a cartridge which is used to generate gas that is dissolved into the precursor liquid. A beverage medium, such as a powdered drink mix or liquid syrup, may be provided in the same, or a separate cartridge as the gas source and mixed with the precursor liquid to form a beverage. The use of one or more cartridges for the gas source and/or beverage medium may make for an easy to use and mess-free system for making sparkling beverages, e.g., in the consumer's home.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.